Skip to main content
. 2011 May 4;22(10):1191–1200. doi: 10.1089/hum.2011.052

FIG. 4.

FIG. 4.

Visual function is preserved in 10-month-old DBA/2J mice treated with rAAV2/5.CMV.Epo or rAAV2/5.CMV.EpoR76E. (A) Average waveforms of the flash visual evoked potential (F-VEP) in control and treated mice. (B–E) Bar graphs of the peak amplitudes of (B) N1 and (C) P1 waves and the latency of the (D) N1 and (E) P1 waves. Data represent means±SEM, and statistical analysis was done by one-way analysis of variance with pair-wise Bonferroni post hoc test; *p≤0.01; **p≤0.001 versus rAAV2/5.CMV.eGFP. There was no statistically significant difference in the N1 and P1 peak amplitude between the preglaucomatous control mice, the rAAV2/5.CMV.Epo-treated mice, and the rAAV2/5.CMV.EpoR76E-treated mice. There was no statistically significant difference in the peak latency of the N1 and P1 waves between any of the treatment groups and the preglaucomatous control mice. The up arrow (↑) in (A) indicates a flash of light.